Completed peer reviews since:
June 5, 2020
Drug Target Insights is committed to a fair and transparent publication policy. The Editor in Chief and his board are primarily responsible for ensuring a fair review process at the end of which a final decision will be made and notified to the authors. The Editor in Chief is also responsible to select and appoint new members of the board.
Editorial board members (including the Editor in Chief) do not process their own work. Submissions they make to the journal are assigned to independent editors and reviewers, who do not have any conflict of interest with the manuscript and authors. The Journal and its Editors and the Publisher are in agreement that any advertising or commercial revenue will in no way influence editorial decisions.
Drug Target Insights publishes manuscripts under Creative Commons licenses; article publication is free of charge and fully funded by the sponsor societies. Please visit the open access and copyright section for full details.
All submission to Drug Target Insights are initially screened by the Editorial Office who performs a technical check based on the manuscript being a) complete in all its parts and b) not present potentially plagiarized contents. All manuscripts submitted to the Journal are screened using iThenticate by CrossCheck.
All suitable submissions are then assigned to the Section Editor or Editor in Chief who will perform an editorial screening to evaluate manuscript which are a) suitable for the section, b) with a sound author background and c) presenting topics of relevance to the journal’s readership. If it is not deemed appropriate it will be rejected immediately. The Section Editor or Editor in Chief will be in charge of selecting and inviting reviewers, evaluating their comments and submitting an editorial recommendation.
The Editor in Chief will finalize the decision and will inform the authors. The final decision is based on the adequacy of comments supplied by the selected reviewers, the replies supplied by the authors in their revisions and the overall quality of the manuscript. The Editor in Chief can select from accept, reject, ask for revisions or invite additional reviewer(s).
Should a revision be recommended, we ask authors to return their revised submission with a point-by-point reply within 2 to 4 weeks. Depending on the extent of changes suggested and how the authors have improved their manuscript, a second round of review may be required.
Drug Target Insights adopts a single anonymized peer-review process, which means that reviewer identity is not made visible to authors, author identity is visible to reviewers, reviewer and author identity are visible to the editors. Reviewers are asked to supply confidential comments and recommendations, which will only be visible to the Section Editor and Editor in Chief, and comments for the authors which are shared in an anonymous way. We invite both external reviewers and members of the Editorial Board, and allow reviewers suggested by authors, although their invitation is decided by the Editors. We allow 7 days for them to agree or decline to perform the review, asking to return their comments within 2 to 4 weeks from accepting the review assignment. Reviewer reports are confidential and are not posted with the articles. Editorials and correspondence may be reviewed and accepted by Editor’s decision. No information about the review process or editorial decision process is published.
Peer review details:
identity transparency: single anonymized
Reviewer interacts with: Editor in Chief and Section Editors
Review information published: none
Accepted submissions will be processed in order of acceptance. Upon acceptance, the corresponding authors will receive a "Licence to Publish” and "Article Processing Charge" forms which will need to be signed and returned to the Publisher in order to proceed with the publication process. The manuscript will then be assigned to a production editor in charge of the entire publication process, who will assign it to style editors with a vast experience in the field the article reports on. No charge is made to the authors for language editing. The corresponding author will receive proofs, which will include all changes made by the style editor, to be corrected and returned within 48 hours. It is the corresponding author’s responsibility to ensure that there are no errors in the proofs. Once approved by the corresponding author, your article will be published online immediately: it will have a DOI number and be fully citable, free to read and download to all.
The final responsibility for published contents rests with the authors and the statements and opinions are solely those of the individual authors and contributors.
For appeals against an editorial decision, please send an email to the Editor in Chief through the Editorial office (firstname.lastname@example.org), indicating clearly your concerns, documenting as appropriate your case.
Errata and corrections
Publishing an errata or a correction may be required in case an article has been published with major errors: it must cite the original article and report relevant amendments.
A retraction may be required for major faults in the manuscript: this can be authored either by the authors of the original article or by the Editor and should clearly report the reasons for article retraction, as well as including a complete citation to the original, retracted article. Retractions must be published in a numbered page of the journal to ensure appropriate indexing.
Letters to the Editor and letters in reply are intended to present opinions or comments on articles published in the Journal. Refer to content type for detailed specifications.
Publisher’s ethical standards
The publisher is committed to a fair, ethical and transparent handling of all editorial operations. Its objective is to select and deploy a reliable system to support the submission, peer-review, publication and post publication process, including publishing corrections and retractions if required, as well as establishing connections which are vital for the exchange of data in the ever developing publishing scenario. Each figure involved must ensure an ethical approach, thus:
The Publisher should: